Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is considered to be an independent risk factor in the progression of chronic kidney diseases (CKD). It can induce kidney fibrosis by increasing transforming growth factor (TGF)-b1 expression, but its molecular mechanism is unclear. The aim of the present study was to investigate the role of actin cytoskeleton in ADMA-induced TGF-b1 high expression in human renal glomerular endothelial cells (HRGECs). The structure of stress fibers was visualized by immunofluorescence, nuclear factor-kB (NF-kB) DNA-binding activity was assessed by an electrophoretic mobility shift assay and TGF-b1 expression was assessed by western blot analysis. Results showed that ADMA induced the assembly of stress fibers, DNA binding of NF-kB, and increasing expression of TGF-b1. When the dynamics of actin cytoskeleton was perturbed by the actin-depolymerizing agent cytochalasin D and the actin-stabilizing agent jasplakinolide, or ablation of stress fiber bundles by the nicotineamide adenine dinucleotide phosphate oxidase inhibitor apocynin and p38 mitogen-activated protein kinase inhibitor SB203580, ADMA-induced DNA binding of NF-kB and TGF-b1 expression were inhibited. These results revealed an actin cytoskeleton-dependent mechanism in ADMA-induced NF-kB activation and TGFb1 high expression in HRGECs. The specific targeting of the actin cytoskeleton may be a useful strategy to prevent ADMA-activated kidney fibrosis in CKD.
Introduction
Asymmetric dimethylarginine (ADMA), a uremia toxin, is a naturally occurring molecule that inhibits the activity of nitric oxide (NO) synthases responsible for NO production [1] . NO deficiency is a major feature of chronic kidney diseases (CKD) involving hypertension, platelet aggregation, and vascular disease development [2] . For patients with CKD, ADMA is a useful biomarker for predicting cardiovascular events [3] . It had been shown that renal dysfunction progression was faster in patients with high ADMA plasma level, and also suggested that ADMA might be an independent progression factor of CKD [4, 5] . High level of ADMA induces renal fibrosis by mechanisms involving oxidative stress and transforming growth factor (TGF)-b1 expression [6] . However, the molecular mechanism of ADMA-induced TGF-b expression is unclear.
Nuclear factor-kB (NF-kB) is a ubiquitously expressed family of transcription factors controlling various biological effects. It is a typical heterodimer of p50 and RelA/p65 subunits and mostly sequestered in the cytoplasm. Upon certain stimuli, NF-kB translocates into the nucleus and subsequently binds to responsive elements to activate target gene transcription. Some studies have revealed the existence of actin cytoskeleton-dependent and -independent pathways that might be involved in a stimulus-specific manner to facilitate NF-kB nuclear import [7] . ADMA can activate some key signaling molecules that regulate actin cytoskeleton structures, such as GTPases RhoA [8] , nicotineamide adenine dinucleotide phosphate (NADPH) oxidase and p38 mitogen-activated protein kinase (MAPK) [9] . Therefore, in the present study, the role of actin cytoskeleton in modulating ADMA-induced NF-kB activation and TGF-b expression in human renal glomerular endothelial cells (HRGECs) was investigated.
Materials and Methods
Cell culture and treatment Primary HRGECs were purchased from ScienCell Research Laboratories (San Diego, USA). Cells were cultured into
fibronectin-coated flasks using endothelial cell medium (ScienCell Research Laboratories) with growth additives and 5% fetal bovine serum. Medium was changed every 2 days. Actively proliferating HRGECs at the third passage were used for experiments.
To observe the effect of ADMA-induced TGF-b1 expression in HRGECs, 80%-90% confluent HRGECs were left to be untreated or incubated with various concentrations of ADMA (5, 50, 100, and 200 mM; Sigma Chemical Corp., St Louis, USA) for 24 h. In some experiments, cells were pretreated separately for 30 min with the actin depolymerizing agent cytochalasin D (Cyto D; 5 mM; Sigma), actin-stabilizing agent jasplakinolide (Jas; 1 mM; CalbiochemNovabiochem Corp., La Jolla, USA), p38 MAPK inhibitor SB203580 (10 mM; Sigma), and NADPH oxidase inhibitor apocynin (100 mM; Sigma), and then 100 mM ADMA was added, followed by incubation for 24 h.
Semi-quantitative real time-polymerase chain reaction Total RNA was isolated with Trizol reagent (Invitrogen, Ontario, Canada) and methyl trichloride according to the manufacturer's instructions. RNA concentration and quality were checked by spectrophotometry. cDNA was synthesized from 1 mg total RNA using oligo (dT) primers and SuperScript III TM reverse transcriptase (Invitrogen) at 428C for 50 min as recommended by the manufacturer. Human TGF-b1 and GAPDH were amplified by the following primers: TGF-b1 (forward, 5 0 -AGACATTCGGGAAGCA GTGCCAG-3 0 and reverse, 5 0 -CATGAGGAGCAGGAAG GGTCGG-3 0 ) and GAPDH (forward, 5 0 -AGACAGCCG CATCTTCTTGT-3 0 and reverse, 5 0 -CCACAGTCTTCTGA GTGGCA-3 0 ). cDNA (2 ml) was amplified in a 50 ml reaction volume containing 0.5 mmol primers and 2.5 units Taq DNA polymerase (TaKaRa, Dalian, China). Polymerase chain reaction conditions were as follows: 40 cycles of 958C for 20 s, 598C for 25 s and 728C for 30 s for TGF-b1 amplification, and 40 cycles of 958C for 30 s, 558C for 30 s and 728C for 1 min for GAPDH amplification. TGF-b1 expression was normalized to GAPDH in the corresponding sample.
Western blot analysis TGF-b1 protein expression in HRGECs was determined by western blot analysis. After the desired incubation period, cells were rinsed with ice-cold phosphate-buffered saline (PBS), lysed and then sonicated. Soluble proteins were separated by 15% sodium dodecyl sulfate-polyacrylamide gels and then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, USA). TGF-b1 protein was detected by immunoblotting with rabbit polyclonal antibodies against human TGF-b1 (1:500; Santa Cruz Biotechnology, Santa Cruz, USA). Immunoreactive bands were visualized with goat anti-rabbit monoclonal antibodies (1:10,000; Santa Cruz) and ECL plus reagent (SUNBIO Corp., Beijing, China). Images were analyzed by densitometry with Labworks Image Acquisition and Analysis Software (Ultra-Violet Products, Ltd, Cambridge, UK). Data were expressed as the ratio between the intensity of TGF-b1 and b-actin.
Electrophoretic mobility shift assay After being incubated with ADMA and inhibitor for the desired period, cells were washed twice with ice-cold Tris-buffered saline and resuspended in 400 ml buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 0.1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM dithiothreitol and 0.5 mM phenylmethylsulfonyl fluoride). After 15 min, Nonidet P-40 was added to a final concentration of 0.6%. Samples were centrifuged to collect supernatants containing cytosolic proteins. Pelleted nuclei were resuspended in 50 ml buffer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride). After 30 min at 48C, lysates were centrifuged and supernatants containing nuclear protein were transferred to new vials.
EMSA was carried out as described previously [10] with some modifications. Briefly, 10 mg nuclear extract was incubated with 1 mg poly (dI-dC) in 20 ml binding buffer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM dithiothreitol, and 10% glycerol) for 15 min at room temperature. Then, end-labeled double-stranded oligonucleotides containing an NF-kB site (30,000 cpm each) were added, and reaction mixtures were incubated for 15 min at room temperature. DNA-protein complexes were resolved in 5% native polyacrylamide gel electrophoresis in low ionic strength buffer (0.25 Â Tris borate/EDTA). The oligonucleotide used for the gel shift analysis was NF-kB 5 0 -AGTTGAGGGGA CTTTCCCAGGC-3 0 . The sequence motif within the oligonucleotides is underlined.
Immunofluorescence
To visualize the distribution of F-actin, HRGECs were fixed with 4% formaldehyde in PBS for 20 min at room temperature and then permeabilized for 10 min with 0.1% Triton X-100. Cells were subsequently incubated with FITC-phalloidin (1 mg/ml; Sigma) for 45 min to stain actin filaments. Single plain images of cells were obtained by confocal laser scanning microscopy (LEICA TCS SP5; Mannheim, Germany).
Statistical analyses
All experiments were performed in triplicate. Data were presented as the mean + standard deviation (SD). Comparisons were performed with one-way analysis of Actin cytoskeleton mediates ADMA-induced TGF-b high expression variance (ANOVA), followed by the least significance difference test. Statistical significance was accepted when P , 0.05. All tests were analyzed with SPSS version 13.0.
Results
Effects of ADMA on actin cytoskeleton reorganization and TGF-b1 expression in HRGECs After 4 days of precisely controlled culture conditions, HRGECs were polygonal in shape and had a few stress fibers traversing the cell body, although there were some stress fibers localized at the cell periphery. ADMA induced the assembly of stress fibers as well as morphological changes. With the increasing concentrations of ADMA, there were many more thick bundles of stress fibers in the cell center, and the cellular shape became irregular (Fig. 1) .
The formation of stress fibers induced by ADMA was accompanied by increased TGF-b1 expression in HRGECs. Treatment with 5 mM of ADMA, a concentration similar to the plasma level of ADMA in CKD patients, failed to induce TGF-b1 high expression within 24 h of stimulation, whereas the increasing of ADMA concentration from 50 to 200 mM caused concentration-dependent expression of TGF-b1 at both mRNA and protein levels (Fig. 2) .
The role of the actin cytoskeleton in modulating ADMA-induced TGF-b1 expression To address the role of actin cytoskeleton in mechanisms of ADMA-induced TGF-b1 expression, Cyto D, a prototypic actin depolymerizing agent, and Jas, a classic actin cytoskeleton stabilizing agent, were firstly used. Results from the analysis of confocal microscopy of HRGECs stained with FITC-labeled phalloidin revealed that pretreatment of cells with Cyto D or Jas perturbed the reorganization of stress fibers induced by ADMA [ Fig. 3(A,B) ]. It was also found that destabilization or stabilization of actin cytoskeleton inhibited ADMA-induced TGF-b1 expression [ Fig. 3(E) ].
Next, apocynin, an NADPH oxidase inhibitor, and SB203580, a p38 MAPK inhibitor, were used to prevent the ADMA-induced increase of stress fibers. Along with inhibition of stress fiber formation [ Fig. 3(C,D) ], the expression of TGF-b1 was decreased significantly [ Fig. 3(F) ]. Results are presented as the fold increase relative to the untreated control. Data are shown as the mean + SD of three independent experiments. *P , 0.05, compared with the control group. n ¼ 5 in each group.
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The role of the actin cytoskeleton in modulating ADMA-induced NF-kB activation We then explored whether preventing the formation of stress fibers could inhibit ADMA-induced NF-kB activation by influencing DNA binding of NF-kB and thereby affecting TGF-b1 expression. EMSA results revealed that control cells showed a faint shift, whereas cells exposed to 100 mM ADMA for 24 h produced a strong shift. In the subsequent experiments, it was found that 5 mM Cyto D and 1 mM Jas both reduced DNA binding of NF-kB in response to ADMA stimulation [ Fig. 4(A) ]. Similar effects were observed in cells that were pretreated with SB203580 or apocynin [ Fig. 4(B) ]. However, Cyto D, Jas, SB203580, and apocynin alone had no effect on NF-kB DNA binding.
Discussion
ADMA is one of the most potent endogenous inhibitors for NO synthases and contributes to cardiovascular morbidity and mortality of CKD sufferers and transplant recipients [3, 11] . Cohort studies of patients with CKD have found that ADMA is an independent risk marker for progression to end-stage renal disease, and is associated with the progression of non-diabetic kidney diseases [4, 5] . To date, the effect of ADMA on the progression of renal fibrosis, and particularly the molecular mechanisms, have not been investigated. Here, we showed a novel role for the actin cytoskeleton in facilitating ADMA-induced NF-kB activation that promoted the expression of TGF-b1, a major profibrotic growth factor in HRGECs.
NF-kB has been implicated in transcriptional control of a number of genes involved in immune and inflammatory responses, growth, and adhesion. It has been reported that ADMA induces NF-kB activation [12] , but the underlying mechanisms are poorly understood. Previous studies have shown that cytoskeleton dynamics are essential for NF-kB nuclear translocation and binding to DNA [7] . Moreover, ADMA can activate some key signaling molecules that regulate the actin cytoskeleton. Therefore, we hypothesized that there might be an actin cytoskeleton-dependent pathway for ADMA-induced NF-kB activation to express TGF-b1.
Two approaches were used to address the role of actin cytoskeleton in ADMA-induced NF-kB activation in Figure 3 Effects of the actin cytoskeleton on modulating ADMA-induced TGF-b1 expression HRGECs were pretreated with the actin depolymerizing agent Cyto D (5 mM), actin stabilizing agent Jas (1 mM), NADPH oxidase inhibitor apocynin (100 mM) or p38 MAPK inhibitor SB203580 (10 mM) for 30 min. Then, cells were either unstimulated or stimulated with 100 mM ADMA for 24 h. Cyto D (A) and Jas (B) perturbed the dynamics of the actin cytoskeleton, while apocynin (C) and SB203580 (D) ablated stress fiber bundles. (E,F) TGF-b1 protein expression was assessed by western blot analysis. TGF-b1 expression normalized to the actin level is expressed as the fold increase relative to the untreated control. Data are shown as the mean + SD of three independent experiments. *P , 0.05, compared with the control group, # P , 0.05, compared with the ADMA-stimulated group. n ¼ 5 in each group.
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HRGECs. First, actin filament stabilization or destabilization was induced to perturb alterations in the actin cytoskeleton that occurred in response to ADMA stimulation. Destabilization of actin filaments was achieved via Cyto D, a classic actin-depolymerizing drug. Cyto D is a cellpermeable fungal toxin that binds to the barbed end of actin filaments, which inhibits both the association and dissociation of subunits at that end, and thus causes disruption of actin filaments and inhibition of actin polymerization [13] . Stabilization of actin filaments was achieved via Jas, a macrocyclic peptide isolated from the marine sponge Jaspis johnstoni [14] . Jas has a cytotoxic effect in vivo by inducing actin polymerization and/or stabilization of preexisting actin filaments. Using these agents, it was found that the disruption of ADMA-induced actin filaments, either by stabilization or destabilization, resulted in marked inhibition of NF-kB DNA binding and TGF-b1 expression. Second, an NADPH oxidase inhibitor and p38 MAPK inhibitor were used to prevent the ADMA-induced increase of stress fibers. p38 MAPK is a member of the MAPK family, which regulates the actin-binding properties of the 27 kDa heat shock protein (HSP27). Reduction of HSP27-induced inhibition of actin polymerization alone can produce stress fiber formation [15] . Reactive oxygen species (ROS) induced by ADMA may be involved in the activation of p38 MAPK, and a major source of ROS in the endothelium is produced via the NADPH oxidase pathway [16, 17] . In the present study, HRGECs pretreated with apocynin or SB203580 were significantly devoid of actin bundles. Together with the inhibition of stress fiber formation, ADMA-induced NF-kB DNA binding and TGF-b1 expression were also inhibited.
TGF-b family cytokines have been found to have diverse roles in regulating growth, differentiation, immune responses, and development of multi-organ systems [18] . There are three isoforms of TGF-b (TGF-b1, TGF-b2, and TGF-b3) in mammalian cells. Several pieces of evidence have implicated TGF-b1 as a major causative agent in the pathogenesis of kidney fibrosis in CKD [19, 20] . In the present study, it was shown that ADMA induced the expression of TGF-b1 in HRGECs, which might have a major role in the progression of CKD. It was also found that activation of NF-kB was essential for TGF-b1 expression after stimulation with ADMA. Preventing actin cytoskeleton reorganization either by perturbing the dynamics or ablating stress fiber bundles could inhibit NF-kB DNA binding and TGF-b1 expression. In short, our findings implied that ADMA might elevate the intracellular ROS level through NADPH oxidase, and ROS was involved in p38 MAPK activation. As a cytoskeleton regulator, the activation of p38 MAPK could induce stress fiber formation, which might facilitate NF-kB nuclear translocation and binding to DNA, and then increased TGF-b1 expression in HRGECs. Thus, specific targeting of the actin cytoskeleton may be a useful strategy for preventing ADMA-activated kidney fibrosis.
Our study might still have several limitations: first, the effective concentrations of ADMA in this study were similar to those reported in two previous studies [21, 22] , which were much higher than the plasma level of ADMA found in patients with uremia. In these typical in vitro experiments, the experimental duration was short; thus, low dose of ADMA failed to increase TGF-b1 expression. The concentration of ADMA in uremic states may increase TGF-b1 expression after longer periods of time Figure 4 Effects of the actin cytoskeleton on ADMA-induced DNA binding of NF-kB HRGECs were pretreated with the actin depolymerizing agent Cyto D (5 mM), actin stabilizing agent Jas (1 mM), NADPH oxidase inhibitor apocynin (100 mM) or p38 MAPK inhibitor SB203580 (10 mM) for 30 min. Then, cells were either unstimulated or stimulated with 100 mM ADMA for 24 h. Nuclear extracts were prepared and then assayed for DNA binding of NF-kB by EMSA. Bar graphs represent the effects of Cyto D and Jas (A), or apocynin and SB203580 (B), on ADMA-induced DNA binding of NF-kB. NF-kB DNA binding is expressed as the fold increase relative to the untreated control. Data are shown as the mean + SD of three independent experiments. *P , 0.05, compared with the control group, # P , 0.05, compared with the ADMA-stimulated group. n ¼ 5 in each group.
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( Supplementary Figs. S1 and S2) , which is relatively difficult to clarify using in vitro systems. Therefore, the effects of long-term stimulation with low-dose ADMA on TGF-b1 expression and kidney fibrosis require further studies in vivo. Second, the inhibitors applied in this study have relatively wide range of effects. There may be cross-talk between p38 MAPK and NF-kB signaling pathways, which is independent of actin cytoskeleton [23] . Moreover, TGF-b1 regulates the actin cytoskeleton directly [24] . These potential signal pathway crosslink effects can not be excluded. As the network of signal pathway is extremely complex, the relationships among ADMA, actin cytoskeleton, NF-kB, and TGF-b are still pending in-depth studies in the future.
In conclusion, the present study provides evidence for an actin cytoskeleton-dependent mechanism in ADMAinduced NF-kB activation and TGF-b expression in HRGECs, which may partly explain the cause of ADMA-activated kidney fibrosis in CKD.
